Company profile
AbCellera
Pipeline4 assets
- ABCL635ABCL635 / NK3R / antibody medicine / Endocrinology / Women's HealthVasomotor Symptoms (VMS) associated with menopausePhase 2active
- ABCL575ABCL575 / OX40L / monoclonal antibody / Immunology & InflammationAtopic Dermatitis (AD)Phase 1active
- ABCL688ABCL688 / Undisclosed GPCR / Ion Channel / antibody medicine / AutoimmunityUndisclosed autoimmunity indicationIND-Enablingactive
- ABCL386ABCL386 / Undisclosed / antibody medicine / OncologyUndisclosed oncology indicationIND-Enablingactive
Latest news14 items
All newsAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Trial Results • Phase 2Top-line results Mon, Aug 10, 2026